Literature DB >> 19258089

Does reperfusion injury still cause significant mortality after lung transplantation?

Gorav Ailawadi1, Christine L Lau, Philip W Smith, Brian R Swenson, Sara A Hennessy, Courtney J Kuhn, Lynn M Fedoruk, Benjamin D Kozower, Irving L Kron, David R Jones.   

Abstract

OBJECTIVES: Severe reperfusion injury after lung transplantation has mortality rates approaching 40%. The purpose of this investigation was to identify whether our improved 1-year survival after lung transplantation is related to a change in reperfusion injury.
METHODS: We reported in March 2000 that early institution of extracorporeal membrane oxygenation can improve lung transplantation survival. The records of consecutive lung transplant recipients from 1990 to March 2000 (early era, n = 136) were compared with those of recipients from March 2000 to August 2006 (current era, n = 155). Reperfusion injury was defined by an oxygenation index of greater than 7 (where oxygenation index = [Percentage inspired oxygen] x [Mean airway pressure]/[Partial pressure of oxygen]). Risk factors for reperfusion injury, treatment of reperfusion injury, and 30-day mortality were compared between eras by using chi(2), Fisher's, or Student's t tests where appropriate.
RESULTS: Although the incidence of reperfusion injury did not change between the eras, 30-day mortality after lung transplantation improved from 11.8% in the early era to 3.9% in the current era (P = .003). In patients without reperfusion injury, mortality was low in both eras. Patients with reperfusion injury had less severe reperfusion injury (P = .01) and less mortality in the current era (11.4% vs 38.2%, P = .01). Primary pulmonary hypertension was more common in the early era (10% [14/136] vs 3.2% [5/155], P = .02). Graft ischemic time increased from 223.3 +/- 78.5 to 286.32 +/- 88.3 minutes in the current era (P = .0001). The mortality of patients with reperfusion injury requiring extracorporeal membrane oxygenation improved in the current era (80.0% [8/10] vs 25.0% [3/12], P = .01).
CONCLUSION: Improved early survival after lung transplantation is due to less severe reperfusion injury, as well as improvements in survival with extracorporeal membrane oxygenation.

Entities:  

Mesh:

Year:  2009        PMID: 19258089     DOI: 10.1016/j.jtcvs.2008.11.007

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  16 in total

1.  Revisiting successful transplantation with marginal lungs: Fourteen years later, a new era of extended criteria.

Authors:  J Hunter Mehaffey; Robert B Hawkins; Eric J Charles; Curtis G Tribble
Journal:  J Thorac Cardiovasc Surg       Date:  2016-08-29       Impact factor: 5.209

2.  Nitrite attenuates mitochondrial impairment and vascular permeability induced by ischemia-reperfusion injury in the lung.

Authors:  Ajay Kumar; Kentaro Noda; Brian Philips; Murugesan Velayutham; Donna B Stolz; Mark T Gladwin; Sruti Shiva; Jonathan D'Cunha
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-02-19       Impact factor: 5.464

3.  Acute hyperglycemic exacerbation of lung ischemia-reperfusion injury is mediated by receptor for advanced glycation end-products signaling.

Authors:  Damien J Lapar; Vanessa A Hajzus; Yunge Zhao; Christine L Lau; Brent A French; Irving L Kron; Ashish K Sharma; Victor E Laubach
Journal:  Am J Respir Cell Mol Biol       Date:  2011-10-06       Impact factor: 6.914

4.  Attenuation of Pulmonary Ischemia-Reperfusion Injury by Adenosine A2B Receptor Antagonism.

Authors:  Mary E Huerter; Ashish K Sharma; Yunge Zhao; Eric J Charles; Irving L Kron; Victor E Laubach
Journal:  Ann Thorac Surg       Date:  2016-04-22       Impact factor: 4.330

5.  Pretreatment strategy with adenosine A2A receptor agonist attenuates reperfusion injury in a preclinical porcine lung transplantation model.

Authors:  Damien J LaPar; Victor E Laubach; Abbas Emaminia; Ivan K Crosby; Vanessa A Hajzus; Ashish K Sharma; Heather M Sumner; David V Webb; Christine L Lau; Irving L Kron
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-16       Impact factor: 5.209

6.  Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury.

Authors:  Leo M Gazoni; Dustin M Walters; Eric B Unger; Joel Linden; Irving L Kron; Victor E Laubach
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-15       Impact factor: 5.209

7.  Natural killer T cell-derived IL-17 mediates lung ischemia-reperfusion injury.

Authors:  Ashish K Sharma; Damien J LaPar; Yunge Zhao; Li Li; Christine L Lau; Irving L Kron; Yoichiro Iwakura; Mark D Okusa; Victor E Laubach
Journal:  Am J Respir Crit Care Med       Date:  2011-02-11       Impact factor: 21.405

8.  Tissue-derived proinflammatory effect of adenosine A2B receptor in lung ischemia-reperfusion injury.

Authors:  Farshad Anvari; Ashish K Sharma; Lucas G Fernandez; Tjasa Hranjec; Katya Ravid; Irving L Kron; Victor E Laubach
Journal:  J Thorac Cardiovasc Surg       Date:  2010-07-24       Impact factor: 5.209

9.  Influence of hemodialysis on clinical outcomes after lung transplantation.

Authors:  Sara A Hennessy; Jacob R Gillen; Tjasa Hranjec; Benjamin D Kozower; David R Jones; Irving L Kron; Christine L Lau
Journal:  J Surg Res       Date:  2013-02-26       Impact factor: 2.192

10.  Receptor for advanced glycation end products (RAGE) on iNKT cells mediates lung ischemia-reperfusion injury.

Authors:  A K Sharma; D J LaPar; M L Stone; Y Zhao; I L Kron; V E Laubach
Journal:  Am J Transplant       Date:  2013-07-19       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.